Skip to content

Parkin Mutations and Their Functional Consequences

Parkin Mutations and Their Functional Consequences

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00136721
Enrollment
2500
Registered
2005-08-29
Start date
2005-02-08
Completion date
2021-02-07
Last updated
2026-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

Parkinson's disease, phenotype-genotype correlations, mutations spectrum, candidate genes

Brief summary

Parkinson's disease (PD) is the most frequent neurodegenerative disease with a prevalence of 2% over 65 years and because of this high prevalence as the population ages, it is a major problem of public health. An exhaustive repertory of not only parkin mutations in autosomal recessive forms of PD but also in other known genes such as DJ-1, PINK1 and LRRK2, is of major importance for both genetic counseling in families affected with PD and physiopathological approaches to this disease. Through a French network for the study of Parkinson's disease genetics and extended collaborations with European, Mediterranean and other various countries, a total of 2934 subjects including 1683 patients and 1251 unaffected individuals has been collected since 2002. These samples consisted of 122 families with autosomal recessive PD, 285 cases of isolated early onset PD, 110 autosomal recessive and 129 autosomal dominant families with late onset PD, 201 isolated late onset PD cases and 250 matched controls. DNAs from all subjects are now available, lymphocytes and lymphoblastoid cell lines have been stored for most patients from France and recently, fresh fibroblasts have been obtained for some individuals. The genetic approach to autosomal recessive PD is focused on the identification of mutations in the parkin gene but also on the screening of DJ-1, PINK1 and LRRK2 genes.

Interventions

None listed

Sponsors

Institut National de la Santé Et de la Recherche Médicale, France
Lead SponsorOTHER_GOV
National Institutes of Health (NIH)
CollaboratorNIH

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients presenting with Parkinson's disease, with a family history or not, * Minors presenting clinical signs of the disease, * Controls (without signs of the disease, matched by sex and age with the patients, relatives for the familial cases)

Exclusion criteria

* Persons refusing to sign the informed consent, * Lack of clinical information

Design outcomes

Primary

MeasureTime frameDescription
Genetic analysisDay 1On DNA extracted from a blood sample collected on EDTA and Lithium heparitane
Transcryptome analysisDay 1On RNA extracted from a blood sample collected on PAX-Gene

Countries

France

Contacts

PRINCIPAL_INVESTIGATORAlexis Brice, MD

Assistance Publique - Hôpitaux de Paris, University Paris 6

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026